Drug Profile
Elismetrep - Mitsubishi Tanabe Pharma
Alternative Names: MT 8554Latest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Class Benzoic acids; Cyclopropanes; Isoquinolines; Neuroprotectants; Small molecules; Sulfonamides
- Mechanism of Action TRPM8 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diabetic neuropathies; Vasomotor symptoms
- No development reported Neurological disorders
Most Recent Events
- 08 Nov 2022 Mitsubishi Tanabe Pharma Corporation completes a phase II trial for Diabetic neuropathies (PO) (NCT05123196)
- 07 Feb 2022 MT 8554 is still in phase II trials for Vasomotor symptoms in the US and globally (Mitsubishi Tanabe Pharma pipeline, February 2022)
- 30 Dec 2021 Phase-II clinical trials in Diabetic neuropathies in Japan (PO) (NCT05123196)